Neuropsychologist Dr Paul Wicks joins the ranks of Cambridge, UK-based precision medicine scaleup Sano Genetics today, where he will take up the full-time role of vice president of neuroscience.
For the past five years, Dr Wicks has been an independent scientific advisor in digital health, clinical trials, rare disease and patient centricity for Sano and other companies.
In his new role with Sano, Dr Wicks - who has worked in the field of amyotrophic lateral sclerosis (ALS) - will lead Sano’s unique ‘Light the Way’ program, which offers peer support, DNA testing, genetic counselling, education and research access to those diagnosed with or experiencing symptoms, as well as those at risk of genetic ALS/motor neurone disease (MND).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze